Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%

Healthcare

Page 49
  1. Mar 11, 2026 · 19:55 · QNTM

    Quantum BioPharma Provides Corporate Update

    Quantum BioPharma Provides Corporate Update

    01
  2. Mar 11, 2026 · 19:53 · NRX

    Nurexone signs consulting agreement, closes financing

    Nurexone signs consulting agreement, closes financing

    02
  3. Mar 11, 2026 · 18:42 · INNO

    Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest

    Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest

    03
  4. Mar 11, 2026 · 17:34 · RVV

    Revive Therapeutics advances bucillamine patents

    Revive Therapeutics advances bucillamine patents

    04
  5. Mar 11, 2026 · 17:15 · VIVI

    Tempramed's Vivi Cap evaluated for summer travel use

    Tempramed's Vivi Cap evaluated for summer travel use

    05
  6. Mar 11, 2026 · 16:17 · AIAI

    Netramark signs contract for client's depression trial

    Netramark signs contract for client's depression trial

    06
  7. Mar 11, 2026 · 08:28 · NRX

    NurExone Announces Corporate Updates

    NurExone Announces Corporate Updates

    07
  8. Mar 11, 2026 · 07:30 · RVV

    Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

    Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

    08
  9. Mar 11, 2026 · 07:01 · VIVI

    TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap

    TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap

    09
  10. Mar 11, 2026 · 07:00 · AIAI

    NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data

    NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data

    10
  11. Mar 10, 2026 · 19:45 · QNTM

    Quantum BioPharma Provides Corporate Update

    Quantum BioPharma Provides Corporate Update

    11
  12. Mar 10, 2026 · 17:40 · KNE

    Kane Biotech signs with U.S. gov't distributor

    Kane Biotech signs with U.S. gov't distributor

    12
  13. Mar 10, 2026 · 17:39 · SPLY

    Safe Supply receives vendor status in Boca Raton

    Safe Supply receives vendor status in Boca Raton

    13
  14. Mar 10, 2026 · 17:26 · TLT

    Theralase Technologies closes $1.1-million financing

    Theralase Technologies closes $1.1-million financing

    14
← Newer Older →